In a multicentre observational study of 22 patients with adult-onset IgA vasculitis, 90.9% (n = 20) achieved remission (as defined by Birmingham Vasculitis Activity Score; BVAS) at an average follow-up of 24 months when receiving rituximab either as monotherapy or as an additional therapy. Following the initiation of rituximab, patients experienced reductions in BVAS (P < 0.0001) and levels of proteinuria (P < 0.0001) and C-reactive protein (P = 0.0005), and were able to reduce their dose of prednisone. Of those patients who achieved remission, 35% (n = 7) subsequently experienced a relapse.
References
Maritati, F. et al. Rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Schönlein purpura). Arthritis Rheumatol. http://dx.doi.org/10.1002/art.40339 (2017)
Rights and permissions
About this article
Cite this article
Collison, J. Rituximab for adult-onset IgA vasculitis. Nat Rev Rheumatol 13, 694 (2017). https://doi.org/10.1038/nrrheum.2017.178
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.178